AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Alex Reid was wrongly advised on early vaccination due to a clinical mistake 17 years earlier. The firm said the decision was taken because of a decline in demand for the vaccine.

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...